Janux Therapeutics (JANX) Depreciation & Amortization (CF) (2020 - 2026)
Janux Therapeutics (JANX) reported Depreciation & Amortization (CF) of $469000.0 for Q1 2026, down 9.63% year-over-year from $519000.0 in Q1 2025, and little changed on a QoQ basis from $468000.0 in Q4 2025.
Janux Therapeutics (JANX) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $469000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 9.63% year-over-year to $469000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 3.32% YoY) and the FY2025 annual result came in at $2.0 million, down 1.5% from the prior year.
- Depreciation & Amortization (CF) steadied at $469000.0 in Q1 2026 per JANX's latest filing, from $468000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $541000.0 in Q2 2025 and bottomed at $81000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $500000.0 (2023), against an average of $432588.2.
- The widest annual swing landed in 2022, when Depreciation & Amortization (CF) jumped 822.22%; it then decreased 9.63% in 2026.
- Tracing JANX's Depreciation & Amortization (CF) over 5 years: stood at $403000.0 in 2022, then surged by 31.76% to $531000.0 in 2023, then dropped by 3.58% to $512000.0 in 2024, then dropped by 8.59% to $468000.0 in 2025, then gained by 0.21% to $469000.0 in 2026.
- Per Business Quant, the three latest JANX Depreciation & Amortization (CF) figures stand at $469000.0 (Q1 2026), $468000.0 (Q4 2025), and $501000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Janux Therapeutics | 914.29 Mn | 914.29 Mn | - | 469,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 469,000.00 |
| Mar 31, 2026 | 469,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Dec 31, 2025 | 468,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Jun 30, 2025 | 541,000.00 |
| Jun 30, 2025 | 541,000.00 |
| Mar 31, 2025 | 519,000.00 |
| Mar 31, 2025 | 519,000.00 |
| Dec 31, 2024 | 512,000.00 |
| Dec 31, 2024 | 512,000.00 |
| Sep 30, 2024 | 510,000.00 |
| Sep 30, 2024 | 510,000.00 |
| Jun 30, 2024 | 506,000.00 |
| Jun 30, 2024 | 506,000.00 |
| Mar 31, 2024 | 532,000.00 |
| Mar 31, 2024 | 532,000.00 |
| Dec 31, 2023 | 531,000.00 |
| Dec 31, 2023 | 531,000.00 |
| Sep 30, 2023 | 500,000.00 |
| Sep 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 471,000.00 |
| Jun 30, 2023 | 471,000.00 |
| Mar 31, 2023 | 453,000.00 |
| Mar 31, 2023 | 453,000.00 |
| Dec 31, 2022 | 403,000.00 |
| Dec 31, 2022 | 403,000.00 |
| Sep 30, 2022 | 249,000.00 |
| Sep 30, 2022 | 249,000.00 |
| Jun 30, 2022 | 108,000.00 |
| Jun 30, 2022 | 108,000.00 |
| Mar 31, 2022 | 81,000.00 |
| Mar 31, 2022 | 81,000.00 |
| Dec 31, 2021 | 64,000.00 |
| Dec 31, 2021 | 64,000.00 |
| Sep 30, 2021 | 27,000.00 |
| Sep 30, 2021 | 27,000.00 |
| Jun 30, 2021 | 13,000.00 |
| Jun 30, 2021 | 13,000.00 |
| Mar 31, 2021 | 9,000.00 |
| Mar 31, 2021 | 9,000.00 |
| Dec 31, 2020 | 9,000.00 |
| Dec 31, 2020 | 9,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Sep 30, 2020 | 1,000.00 |